Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 596 participants.

Also called NCT07047014

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 596 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07047014
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07047014. Randomized; single masking; primary purpose treatment. Start 2025-07-30 (actual); primary completion 2027-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ischemic Stroke
Acronym
ARTS-MeVO
Condition
Stroke, Ischemic
Condition
Medium Vessel Occlusions
Intervention (Drug)
Tenecteplase (0.25mg/kg)
Intervention (Drug)
Standard medical treatment
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
First Affiliated Hospital of Zhejiang University (class: other)
Collaborator
Chinese Stroke Association (class: not stated)

Record details

Record id
cardio:ct-nct07047014
Content hash
983dd63153150650454e7e26ee6aa345a717bed201b85be91935c377c2ffc629